Shots:

• Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex's sole discretion in either cash or additional Athenex common stock (or a combination of both)
• The acquisition will expand Athenex’s cell therapy development capability with Kuur’s off-the-shelf engineered CAR-NKT platform and allow the companies to combine CARs and TCRs with the NKT cell platform to target hematological and solid cancers- respectively
• The platform has the potential to provide synergies with other assets in Athenex’s pipeline

  Ref: GLOBE NEWSWIRE | Image: Athenex